1776 Yorktown
Suite 550
Houston, TX 77056
United States
(832) 260-0222
https://www.nexalin.com
Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 6
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Ms. Marilyn Elson | Controller | 382,72k | S.O. | 1953 |
Mr. Mark White | President, CEO, CFO & Director | 191,29k | S.O. | 1962 |
Mr. John Patrick Claude | Co-Founder and Director of Engineering & Development | S.O. | S.O. | S.O. |
Dr. David Owens M.D. | Chief Medical Officer & Director | S.O. | S.O. | 1961 |
Mr. Michael Nketiah | Senior Vice-President of Quality, Regulatory & Clinical Affairs | 251,6k | S.O. | 1976 |
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
L’ISS Governance QualityScore de Nexalin Technology, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..